Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada Article Swipe
Jennifer Fenna
,
Daniel McCormack
,
Sophie A. Kitchen
,
Diana Martins
,
Tara Gomes
,
Mina Tadrous
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.18553/jmcp.2021.27.4.444
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.18553/jmcp.2021.27.4.444
BACKGROUND: Use of costly biologic drugs for the treatment of chronic inflammatory diseases has increased significantly in recent years. However, biosimilar drugs offer an opportunity to ensure health system sustainability with robust uptake. OBJECTIVE: To study the effect of formulary listing strategies on the use of infliximab and etanercept innovator and biosimilar biologics. METHODS: This is a cross-sectional study of individuals in Ontario, Canada, dispensed a biologic prescription for infliximab or etanercept through Ontario's public drug program between January 1, 2010, and June 30, 2019. Quarterly utilization and costs were forecasted using Holt-Winters' exponential smoothing models to the second quarter (Q2) of 2022. Secondary analyses explored utilization for rheumatic conditions (RC) and inflammatory bowel disease (IBD). RESULTS: From Q1 2010 to Q2 2019, infliximab and etanercept users increased by 75.7% (n = 4,073 to 7,158), with a forecasted increase of 13.7% (n = 8,142; 95% CI = 7,438-8,847) by Q2 2022. Biosimilar users represented 13.8% (n = 539 of 3,905) of total infliximab users in Q2 2019, although this differed by indication with 6.9% for IBD (n = 187 of 2,712) and 26.6% for RC (n = 203 of 764). Etanercept biosimilar users represented 20.2% (n = 659 of 3,256) of total etanercept users for RC in Q2 2019. Biologics expenditures increased 109.7% during the study, amounting to $49.9 million in Q2 2019. CONCLUSIONS: Despite differing reimbursement restrictions between innovator infliximab and etanercept biologics, the uptake of their biosimilars was low and not noticeably different in the treatment of RC. Dynamic policy strategies are needed to improve the uptake of biosimilars, particularly for IBD. DISCLOSURES: Funding for this study was contributed by the Ontario Ministry of Health. The authors have no conflicts of interest to disclose.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.18553/jmcp.2021.27.4.444
- https://www.jmcp.org/doi/pdf/10.18553/jmcp.2021.27.4.444
- OA Status
- bronze
- Cited By
- 3
- References
- 23
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3137020909
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3137020909Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.18553/jmcp.2021.27.4.444Digital Object Identifier
- Title
-
Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, CanadaWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-04-01Full publication date if available
- Authors
-
Jennifer Fenna, Daniel McCormack, Sophie A. Kitchen, Diana Martins, Tara Gomes, Mina TadrousList of authors in order
- Landing page
-
https://doi.org/10.18553/jmcp.2021.27.4.444Publisher landing page
- PDF URL
-
https://www.jmcp.org/doi/pdf/10.18553/jmcp.2021.27.4.444Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://www.jmcp.org/doi/pdf/10.18553/jmcp.2021.27.4.444Direct OA link when available
- Concepts
-
Biosimilar, Infliximab, Medicine, Etanercept, Formulary, Reimbursement, Pharmacology, Internal medicine, Health care, Tumor necrosis factor alpha, Economic growth, EconomicsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
3Total citation count in OpenAlex
- Citations by year (recent)
-
2022: 2, 2021: 1Per-year citation counts (last 5 years)
- References (count)
-
23Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3137020909 |
|---|---|
| doi | https://doi.org/10.18553/jmcp.2021.27.4.444 |
| ids.doi | https://doi.org/10.18553/jmcp.2021.27.4.444 |
| ids.mag | 3137020909 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/33769851 |
| ids.openalex | https://openalex.org/W3137020909 |
| fwci | 0.30966459 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000328 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Adult |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D000368 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Aged |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D000369 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Aged, 80 and over |
| mesh[3].qualifier_ui | Q000008 |
| mesh[3].descriptor_ui | D018501 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | administration & dosage |
| mesh[3].descriptor_name | Antirheumatic Agents |
| mesh[4].qualifier_ui | Q000627 |
| mesh[4].descriptor_ui | D018501 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | therapeutic use |
| mesh[4].descriptor_name | Antirheumatic Agents |
| mesh[5].qualifier_ui | Q000188 |
| mesh[5].descriptor_ui | D001172 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | drug therapy |
| mesh[5].descriptor_name | Arthritis, Rheumatoid |
| mesh[6].qualifier_ui | Q000008 |
| mesh[6].descriptor_ui | D059451 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | administration & dosage |
| mesh[6].descriptor_name | Biosimilar Pharmaceuticals |
| mesh[7].qualifier_ui | Q000627 |
| mesh[7].descriptor_ui | D059451 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | therapeutic use |
| mesh[7].descriptor_name | Biosimilar Pharmaceuticals |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D003430 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Cross-Sectional Studies |
| mesh[9].qualifier_ui | Q000008 |
| mesh[9].descriptor_ui | D000068800 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | administration & dosage |
| mesh[9].descriptor_name | Etanercept |
| mesh[10].qualifier_ui | Q000627 |
| mesh[10].descriptor_ui | D000068800 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | therapeutic use |
| mesh[10].descriptor_name | Etanercept |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D005260 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Female |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D006801 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Humans |
| mesh[13].qualifier_ui | Q000188 |
| mesh[13].descriptor_ui | D015212 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | drug therapy |
| mesh[13].descriptor_name | Inflammatory Bowel Diseases |
| mesh[14].qualifier_ui | Q000008 |
| mesh[14].descriptor_ui | D000069285 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | administration & dosage |
| mesh[14].descriptor_name | Infliximab |
| mesh[15].qualifier_ui | Q000627 |
| mesh[15].descriptor_ui | D000069285 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | therapeutic use |
| mesh[15].descriptor_name | Infliximab |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D008297 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Male |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D008875 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Middle Aged |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D009864 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Ontario |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D010593 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Pharmaceutical Services |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D055815 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Young Adult |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D000328 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Adult |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D000368 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Aged |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D000369 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Aged, 80 and over |
| mesh[24].qualifier_ui | Q000008 |
| mesh[24].descriptor_ui | D018501 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | administration & dosage |
| mesh[24].descriptor_name | Antirheumatic Agents |
| mesh[25].qualifier_ui | Q000627 |
| mesh[25].descriptor_ui | D018501 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | therapeutic use |
| mesh[25].descriptor_name | Antirheumatic Agents |
| mesh[26].qualifier_ui | Q000188 |
| mesh[26].descriptor_ui | D001172 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | drug therapy |
| mesh[26].descriptor_name | Arthritis, Rheumatoid |
| mesh[27].qualifier_ui | Q000008 |
| mesh[27].descriptor_ui | D059451 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | administration & dosage |
| mesh[27].descriptor_name | Biosimilar Pharmaceuticals |
| mesh[28].qualifier_ui | Q000627 |
| mesh[28].descriptor_ui | D059451 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | therapeutic use |
| mesh[28].descriptor_name | Biosimilar Pharmaceuticals |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D003430 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Cross-Sectional Studies |
| mesh[30].qualifier_ui | Q000008 |
| mesh[30].descriptor_ui | D000068800 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | administration & dosage |
| mesh[30].descriptor_name | Etanercept |
| mesh[31].qualifier_ui | Q000627 |
| mesh[31].descriptor_ui | D000068800 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | therapeutic use |
| mesh[31].descriptor_name | Etanercept |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D005260 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Female |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D006801 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Humans |
| mesh[34].qualifier_ui | Q000188 |
| mesh[34].descriptor_ui | D015212 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | drug therapy |
| mesh[34].descriptor_name | Inflammatory Bowel Diseases |
| mesh[35].qualifier_ui | Q000008 |
| mesh[35].descriptor_ui | D000069285 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | administration & dosage |
| mesh[35].descriptor_name | Infliximab |
| mesh[36].qualifier_ui | Q000627 |
| mesh[36].descriptor_ui | D000069285 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | therapeutic use |
| mesh[36].descriptor_name | Infliximab |
| mesh[37].qualifier_ui | |
| mesh[37].descriptor_ui | D008297 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | |
| mesh[37].descriptor_name | Male |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D008875 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | Middle Aged |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D009864 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Ontario |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D010593 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Pharmaceutical Services |
| mesh[41].qualifier_ui | |
| mesh[41].descriptor_ui | D055815 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | |
| mesh[41].descriptor_name | Young Adult |
| mesh[42].qualifier_ui | |
| mesh[42].descriptor_ui | D000328 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | |
| mesh[42].descriptor_name | Adult |
| mesh[43].qualifier_ui | |
| mesh[43].descriptor_ui | D000368 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | |
| mesh[43].descriptor_name | Aged |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D000369 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | Aged, 80 and over |
| mesh[45].qualifier_ui | Q000008 |
| mesh[45].descriptor_ui | D018501 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | administration & dosage |
| mesh[45].descriptor_name | Antirheumatic Agents |
| mesh[46].qualifier_ui | Q000627 |
| mesh[46].descriptor_ui | D018501 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | therapeutic use |
| mesh[46].descriptor_name | Antirheumatic Agents |
| mesh[47].qualifier_ui | Q000188 |
| mesh[47].descriptor_ui | D001172 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | drug therapy |
| mesh[47].descriptor_name | Arthritis, Rheumatoid |
| mesh[48].qualifier_ui | Q000008 |
| mesh[48].descriptor_ui | D059451 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | administration & dosage |
| mesh[48].descriptor_name | Biosimilar Pharmaceuticals |
| mesh[49].qualifier_ui | Q000627 |
| mesh[49].descriptor_ui | D059451 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | therapeutic use |
| mesh[49].descriptor_name | Biosimilar Pharmaceuticals |
| type | article |
| title | Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada |
| biblio.issue | 4 |
| biblio.volume | 27 |
| biblio.last_page | 452 |
| biblio.first_page | 444 |
| topics[0].id | https://openalex.org/T12255 |
| topics[0].field.id | https://openalex.org/fields/24 |
| topics[0].field.display_name | Immunology and Microbiology |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2403 |
| topics[0].subfield.display_name | Immunology |
| topics[0].display_name | Biosimilars and Bioanalytical Methods |
| topics[1].id | https://openalex.org/T10804 |
| topics[1].field.id | https://openalex.org/fields/20 |
| topics[1].field.display_name | Economics, Econometrics and Finance |
| topics[1].score | 0.9883999824523926 |
| topics[1].domain.id | https://openalex.org/domains/2 |
| topics[1].domain.display_name | Social Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2002 |
| topics[1].subfield.display_name | Economics and Econometrics |
| topics[1].display_name | Health Systems, Economic Evaluations, Quality of Life |
| topics[2].id | https://openalex.org/T12547 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9865000247955322 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2735 |
| topics[2].subfield.display_name | Pediatrics, Perinatology and Child Health |
| topics[2].display_name | Pharmaceutical studies and practices |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C59491497 |
| concepts[0].level | 2 |
| concepts[0].score | 0.9284142255783081 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q864715 |
| concepts[0].display_name | Biosimilar |
| concepts[1].id | https://openalex.org/C2777138892 |
| concepts[1].level | 3 |
| concepts[1].score | 0.899167537689209 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q415264 |
| concepts[1].display_name | Infliximab |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.8647781610488892 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2777226972 |
| concepts[3].level | 3 |
| concepts[3].score | 0.8592672348022461 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q415343 |
| concepts[3].display_name | Etanercept |
| concepts[4].id | https://openalex.org/C100406419 |
| concepts[4].level | 2 |
| concepts[4].score | 0.4851725697517395 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q3543802 |
| concepts[4].display_name | Formulary |
| concepts[5].id | https://openalex.org/C2779703844 |
| concepts[5].level | 3 |
| concepts[5].score | 0.4250012934207916 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q760125 |
| concepts[5].display_name | Reimbursement |
| concepts[6].id | https://openalex.org/C98274493 |
| concepts[6].level | 1 |
| concepts[6].score | 0.31418266892433167 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[6].display_name | Pharmacology |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.3115600347518921 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C160735492 |
| concepts[8].level | 2 |
| concepts[8].score | 0.22486111521720886 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q31207 |
| concepts[8].display_name | Health care |
| concepts[9].id | https://openalex.org/C17991360 |
| concepts[9].level | 2 |
| concepts[9].score | 0.18724018335342407 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q21173843 |
| concepts[9].display_name | Tumor necrosis factor alpha |
| concepts[10].id | https://openalex.org/C50522688 |
| concepts[10].level | 1 |
| concepts[10].score | 0.0 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q189833 |
| concepts[10].display_name | Economic growth |
| concepts[11].id | https://openalex.org/C162324750 |
| concepts[11].level | 0 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q8134 |
| concepts[11].display_name | Economics |
| keywords[0].id | https://openalex.org/keywords/biosimilar |
| keywords[0].score | 0.9284142255783081 |
| keywords[0].display_name | Biosimilar |
| keywords[1].id | https://openalex.org/keywords/infliximab |
| keywords[1].score | 0.899167537689209 |
| keywords[1].display_name | Infliximab |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.8647781610488892 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/etanercept |
| keywords[3].score | 0.8592672348022461 |
| keywords[3].display_name | Etanercept |
| keywords[4].id | https://openalex.org/keywords/formulary |
| keywords[4].score | 0.4851725697517395 |
| keywords[4].display_name | Formulary |
| keywords[5].id | https://openalex.org/keywords/reimbursement |
| keywords[5].score | 0.4250012934207916 |
| keywords[5].display_name | Reimbursement |
| keywords[6].id | https://openalex.org/keywords/pharmacology |
| keywords[6].score | 0.31418266892433167 |
| keywords[6].display_name | Pharmacology |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.3115600347518921 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/health-care |
| keywords[8].score | 0.22486111521720886 |
| keywords[8].display_name | Health care |
| keywords[9].id | https://openalex.org/keywords/tumor-necrosis-factor-alpha |
| keywords[9].score | 0.18724018335342407 |
| keywords[9].display_name | Tumor necrosis factor alpha |
| language | en |
| locations[0].id | doi:10.18553/jmcp.2021.27.4.444 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2764743878 |
| locations[0].source.issn | 2376-0540, 2376-1032 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 2376-0540 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Journal of Managed Care & Specialty Pharmacy |
| locations[0].source.host_organization | https://openalex.org/P4310321168 |
| locations[0].source.host_organization_name | AMCP |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310321168 |
| locations[0].license | |
| locations[0].pdf_url | https://www.jmcp.org/doi/pdf/10.18553/jmcp.2021.27.4.444 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of Managed Care & Specialty Pharmacy |
| locations[0].landing_page_url | https://doi.org/10.18553/jmcp.2021.27.4.444 |
| locations[1].id | pmid:33769851 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Journal of managed care & specialty pharmacy |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/33769851 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:10391289 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | |
| locations[2].pdf_url | https://pmc.ncbi.nlm.nih.gov/articles/PMC10391289/pdf/jmcp.2021.27.4.444.pdf |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | J Manag Care Spec Pharm |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/10391289 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5053120414 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Jennifer Fenna |
| authorships[0].countries | CA, HK |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I185261750 |
| authorships[0].affiliations[0].raw_affiliation_string | University of Toronto, Toronto, Canada. |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I126859394 |
| authorships[0].affiliations[1].raw_affiliation_string | Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services, Alberta Health Services, Edmonton, Alberta, Canada. |
| authorships[0].affiliations[2].raw_affiliation_string | ICES, Toronto, Canada. |
| authorships[0].affiliations[3].institution_ids | https://openalex.org/I126859394 |
| authorships[0].affiliations[3].raw_affiliation_string | Alberta Health Services, Edmonton, Alberta, Canada. |
| authorships[0].affiliations[4].institution_ids | https://openalex.org/I4399598460 |
| authorships[0].affiliations[4].raw_affiliation_string | Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada. |
| authorships[0].affiliations[5].institution_ids | https://openalex.org/I4399598460 |
| authorships[0].affiliations[5].raw_affiliation_string | Unity Health Toronto; and Institute of Health Policy, Management and Evaluation, |
| authorships[0].affiliations[6].institution_ids | https://openalex.org/I185261750, https://openalex.org/I2801816099 |
| authorships[0].affiliations[6].raw_affiliation_string | Faculty of Pharmacy, University of Toronto; ICES; and Women's College Research Institute, Toronto, Canada. |
| authorships[0].affiliations[7].institution_ids | https://openalex.org/I185261750, https://openalex.org/I2800582968 |
| authorships[0].affiliations[7].raw_affiliation_string | Faculty of Pharmacy, University of Toronto; Li Ka Shing Knowledge Institute, |
| authorships[0].institutions[0].id | https://openalex.org/I4399598460 |
| authorships[0].institutions[0].ror | https://ror.org/012x5xb44 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4399598460 |
| authorships[0].institutions[0].country_code | |
| authorships[0].institutions[0].display_name | Unity Health Toronto |
| authorships[0].institutions[1].id | https://openalex.org/I126859394 |
| authorships[0].institutions[1].ror | https://ror.org/02nt5es71 |
| authorships[0].institutions[1].type | healthcare |
| authorships[0].institutions[1].lineage | https://openalex.org/I126859394 |
| authorships[0].institutions[1].country_code | CA |
| authorships[0].institutions[1].display_name | Alberta Health Services |
| authorships[0].institutions[2].id | https://openalex.org/I185261750 |
| authorships[0].institutions[2].ror | https://ror.org/03dbr7087 |
| authorships[0].institutions[2].type | education |
| authorships[0].institutions[2].lineage | https://openalex.org/I185261750 |
| authorships[0].institutions[2].country_code | CA |
| authorships[0].institutions[2].display_name | University of Toronto |
| authorships[0].institutions[3].id | https://openalex.org/I2801816099 |
| authorships[0].institutions[3].ror | https://ror.org/03cw63y62 |
| authorships[0].institutions[3].type | healthcare |
| authorships[0].institutions[3].lineage | https://openalex.org/I2801816099 |
| authorships[0].institutions[3].country_code | CA |
| authorships[0].institutions[3].display_name | Women's College Hospital |
| authorships[0].institutions[4].id | https://openalex.org/I2800582968 |
| authorships[0].institutions[4].ror | https://ror.org/01g6g9h28 |
| authorships[0].institutions[4].type | nonprofit |
| authorships[0].institutions[4].lineage | https://openalex.org/I2800582968 |
| authorships[0].institutions[4].country_code | HK |
| authorships[0].institutions[4].display_name | Li Ka Shing Foundation |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Jennifer Fenna |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Alberta Health Services, Edmonton, Alberta, Canada., Faculty of Pharmacy, University of Toronto; ICES; and Women's College Research Institute, Toronto, Canada., Faculty of Pharmacy, University of Toronto; Li Ka Shing Knowledge Institute,, ICES, Toronto, Canada., Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services, Alberta Health Services, Edmonton, Alberta, Canada., Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada., Unity Health Toronto; and Institute of Health Policy, Management and Evaluation,, University of Toronto, Toronto, Canada. |
| authorships[1].author.id | https://openalex.org/A5088545319 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-3485-6427 |
| authorships[1].author.display_name | Daniel McCormack |
| authorships[1].countries | CA, HK |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I185261750 |
| authorships[1].affiliations[0].raw_affiliation_string | University of Toronto, Toronto, Canada. |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I126859394 |
| authorships[1].affiliations[1].raw_affiliation_string | Alberta Health Services, Edmonton, Alberta, Canada. |
| authorships[1].affiliations[2].institution_ids | https://openalex.org/I4399598460 |
| authorships[1].affiliations[2].raw_affiliation_string | Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada. |
| authorships[1].affiliations[3].institution_ids | https://openalex.org/I4399598460 |
| authorships[1].affiliations[3].raw_affiliation_string | Unity Health Toronto; and Institute of Health Policy, Management and Evaluation, |
| authorships[1].affiliations[4].institution_ids | https://openalex.org/I185261750, https://openalex.org/I2800582968 |
| authorships[1].affiliations[4].raw_affiliation_string | Faculty of Pharmacy, University of Toronto; Li Ka Shing Knowledge Institute, |
| authorships[1].affiliations[5].institution_ids | https://openalex.org/I185261750, https://openalex.org/I2801816099 |
| authorships[1].affiliations[5].raw_affiliation_string | Faculty of Pharmacy, University of Toronto; ICES; and Women's College Research Institute, Toronto, Canada. |
| authorships[1].affiliations[6].raw_affiliation_string | ICES, Toronto, Canada. |
| authorships[1].affiliations[7].institution_ids | https://openalex.org/I185261750 |
| authorships[1].affiliations[7].raw_affiliation_string | Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services, |
| authorships[1].institutions[0].id | https://openalex.org/I4399598460 |
| authorships[1].institutions[0].ror | https://ror.org/012x5xb44 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4399598460 |
| authorships[1].institutions[0].country_code | |
| authorships[1].institutions[0].display_name | Unity Health Toronto |
| authorships[1].institutions[1].id | https://openalex.org/I126859394 |
| authorships[1].institutions[1].ror | https://ror.org/02nt5es71 |
| authorships[1].institutions[1].type | healthcare |
| authorships[1].institutions[1].lineage | https://openalex.org/I126859394 |
| authorships[1].institutions[1].country_code | CA |
| authorships[1].institutions[1].display_name | Alberta Health Services |
| authorships[1].institutions[2].id | https://openalex.org/I185261750 |
| authorships[1].institutions[2].ror | https://ror.org/03dbr7087 |
| authorships[1].institutions[2].type | education |
| authorships[1].institutions[2].lineage | https://openalex.org/I185261750 |
| authorships[1].institutions[2].country_code | CA |
| authorships[1].institutions[2].display_name | University of Toronto |
| authorships[1].institutions[3].id | https://openalex.org/I2801816099 |
| authorships[1].institutions[3].ror | https://ror.org/03cw63y62 |
| authorships[1].institutions[3].type | healthcare |
| authorships[1].institutions[3].lineage | https://openalex.org/I2801816099 |
| authorships[1].institutions[3].country_code | CA |
| authorships[1].institutions[3].display_name | Women's College Hospital |
| authorships[1].institutions[4].id | https://openalex.org/I2800582968 |
| authorships[1].institutions[4].ror | https://ror.org/01g6g9h28 |
| authorships[1].institutions[4].type | nonprofit |
| authorships[1].institutions[4].lineage | https://openalex.org/I2800582968 |
| authorships[1].institutions[4].country_code | HK |
| authorships[1].institutions[4].display_name | Li Ka Shing Foundation |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Daniel McCormack |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Alberta Health Services, Edmonton, Alberta, Canada., Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services,, Faculty of Pharmacy, University of Toronto; ICES; and Women's College Research Institute, Toronto, Canada., Faculty of Pharmacy, University of Toronto; Li Ka Shing Knowledge Institute,, ICES, Toronto, Canada., Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada., Unity Health Toronto; and Institute of Health Policy, Management and Evaluation,, University of Toronto, Toronto, Canada. |
| authorships[2].author.id | https://openalex.org/A5047334918 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-2910-2428 |
| authorships[2].author.display_name | Sophie A. Kitchen |
| authorships[2].countries | CA, HK |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I126859394 |
| authorships[2].affiliations[0].raw_affiliation_string | Alberta Health Services, Edmonton, Alberta, Canada. |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I4399598460 |
| authorships[2].affiliations[1].raw_affiliation_string | Unity Health Toronto; and Institute of Health Policy, Management and Evaluation, |
| authorships[2].affiliations[2].institution_ids | https://openalex.org/I4399598460 |
| authorships[2].affiliations[2].raw_affiliation_string | Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada. |
| authorships[2].affiliations[3].institution_ids | https://openalex.org/I185261750 |
| authorships[2].affiliations[3].raw_affiliation_string | Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services, |
| authorships[2].affiliations[4].raw_affiliation_string | ICES, Toronto, Canada. |
| authorships[2].affiliations[5].institution_ids | https://openalex.org/I185261750, https://openalex.org/I2801816099 |
| authorships[2].affiliations[5].raw_affiliation_string | Faculty of Pharmacy, University of Toronto; ICES; and Women's College Research Institute, Toronto, Canada. |
| authorships[2].affiliations[6].institution_ids | https://openalex.org/I185261750 |
| authorships[2].affiliations[6].raw_affiliation_string | University of Toronto, Toronto, Canada. |
| authorships[2].affiliations[7].institution_ids | https://openalex.org/I185261750, https://openalex.org/I2800582968 |
| authorships[2].affiliations[7].raw_affiliation_string | Faculty of Pharmacy, University of Toronto; Li Ka Shing Knowledge Institute, |
| authorships[2].institutions[0].id | https://openalex.org/I4399598460 |
| authorships[2].institutions[0].ror | https://ror.org/012x5xb44 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4399598460 |
| authorships[2].institutions[0].country_code | |
| authorships[2].institutions[0].display_name | Unity Health Toronto |
| authorships[2].institutions[1].id | https://openalex.org/I126859394 |
| authorships[2].institutions[1].ror | https://ror.org/02nt5es71 |
| authorships[2].institutions[1].type | healthcare |
| authorships[2].institutions[1].lineage | https://openalex.org/I126859394 |
| authorships[2].institutions[1].country_code | CA |
| authorships[2].institutions[1].display_name | Alberta Health Services |
| authorships[2].institutions[2].id | https://openalex.org/I185261750 |
| authorships[2].institutions[2].ror | https://ror.org/03dbr7087 |
| authorships[2].institutions[2].type | education |
| authorships[2].institutions[2].lineage | https://openalex.org/I185261750 |
| authorships[2].institutions[2].country_code | CA |
| authorships[2].institutions[2].display_name | University of Toronto |
| authorships[2].institutions[3].id | https://openalex.org/I2801816099 |
| authorships[2].institutions[3].ror | https://ror.org/03cw63y62 |
| authorships[2].institutions[3].type | healthcare |
| authorships[2].institutions[3].lineage | https://openalex.org/I2801816099 |
| authorships[2].institutions[3].country_code | CA |
| authorships[2].institutions[3].display_name | Women's College Hospital |
| authorships[2].institutions[4].id | https://openalex.org/I2800582968 |
| authorships[2].institutions[4].ror | https://ror.org/01g6g9h28 |
| authorships[2].institutions[4].type | nonprofit |
| authorships[2].institutions[4].lineage | https://openalex.org/I2800582968 |
| authorships[2].institutions[4].country_code | HK |
| authorships[2].institutions[4].display_name | Li Ka Shing Foundation |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Sophie Kitchen |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Alberta Health Services, Edmonton, Alberta, Canada., Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services,, Faculty of Pharmacy, University of Toronto; ICES; and Women's College Research Institute, Toronto, Canada., Faculty of Pharmacy, University of Toronto; Li Ka Shing Knowledge Institute,, ICES, Toronto, Canada., Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada., Unity Health Toronto; and Institute of Health Policy, Management and Evaluation,, University of Toronto, Toronto, Canada. |
| authorships[3].author.id | https://openalex.org/A5088058402 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-1457-8992 |
| authorships[3].author.display_name | Diana Martins |
| authorships[3].countries | CA, HK |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I185261750 |
| authorships[3].affiliations[0].raw_affiliation_string | University of Toronto, Toronto, Canada. |
| authorships[3].affiliations[1].institution_ids | https://openalex.org/I4399598460 |
| authorships[3].affiliations[1].raw_affiliation_string | Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada. |
| authorships[3].affiliations[2].raw_affiliation_string | ICES, Toronto, Canada. |
| authorships[3].affiliations[3].institution_ids | https://openalex.org/I185261750, https://openalex.org/I2800582968 |
| authorships[3].affiliations[3].raw_affiliation_string | Faculty of Pharmacy, University of Toronto; Li Ka Shing Knowledge Institute, |
| authorships[3].affiliations[4].institution_ids | https://openalex.org/I126859394 |
| authorships[3].affiliations[4].raw_affiliation_string | Alberta Health Services, Edmonton, Alberta, Canada. |
| authorships[3].affiliations[5].institution_ids | https://openalex.org/I4399598460 |
| authorships[3].affiliations[5].raw_affiliation_string | Unity Health Toronto; and Institute of Health Policy, Management and Evaluation, |
| authorships[3].affiliations[6].institution_ids | https://openalex.org/I185261750, https://openalex.org/I2801816099 |
| authorships[3].affiliations[6].raw_affiliation_string | Faculty of Pharmacy, University of Toronto; ICES; and Women's College Research Institute, Toronto, Canada. |
| authorships[3].affiliations[7].institution_ids | https://openalex.org/I185261750 |
| authorships[3].affiliations[7].raw_affiliation_string | Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services, |
| authorships[3].institutions[0].id | https://openalex.org/I4399598460 |
| authorships[3].institutions[0].ror | https://ror.org/012x5xb44 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4399598460 |
| authorships[3].institutions[0].country_code | |
| authorships[3].institutions[0].display_name | Unity Health Toronto |
| authorships[3].institutions[1].id | https://openalex.org/I126859394 |
| authorships[3].institutions[1].ror | https://ror.org/02nt5es71 |
| authorships[3].institutions[1].type | healthcare |
| authorships[3].institutions[1].lineage | https://openalex.org/I126859394 |
| authorships[3].institutions[1].country_code | CA |
| authorships[3].institutions[1].display_name | Alberta Health Services |
| authorships[3].institutions[2].id | https://openalex.org/I185261750 |
| authorships[3].institutions[2].ror | https://ror.org/03dbr7087 |
| authorships[3].institutions[2].type | education |
| authorships[3].institutions[2].lineage | https://openalex.org/I185261750 |
| authorships[3].institutions[2].country_code | CA |
| authorships[3].institutions[2].display_name | University of Toronto |
| authorships[3].institutions[3].id | https://openalex.org/I2801816099 |
| authorships[3].institutions[3].ror | https://ror.org/03cw63y62 |
| authorships[3].institutions[3].type | healthcare |
| authorships[3].institutions[3].lineage | https://openalex.org/I2801816099 |
| authorships[3].institutions[3].country_code | CA |
| authorships[3].institutions[3].display_name | Women's College Hospital |
| authorships[3].institutions[4].id | https://openalex.org/I2800582968 |
| authorships[3].institutions[4].ror | https://ror.org/01g6g9h28 |
| authorships[3].institutions[4].type | nonprofit |
| authorships[3].institutions[4].lineage | https://openalex.org/I2800582968 |
| authorships[3].institutions[4].country_code | HK |
| authorships[3].institutions[4].display_name | Li Ka Shing Foundation |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Diana Martins |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Alberta Health Services, Edmonton, Alberta, Canada., Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services,, Faculty of Pharmacy, University of Toronto; ICES; and Women's College Research Institute, Toronto, Canada., Faculty of Pharmacy, University of Toronto; Li Ka Shing Knowledge Institute,, ICES, Toronto, Canada., Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada., Unity Health Toronto; and Institute of Health Policy, Management and Evaluation,, University of Toronto, Toronto, Canada. |
| authorships[4].author.id | https://openalex.org/A5053276850 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-1468-1965 |
| authorships[4].author.display_name | Tara Gomes |
| authorships[4].countries | CA |
| authorships[4].affiliations[0].raw_affiliation_string | ICES, Toronto, Canada. |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I185261750 |
| authorships[4].affiliations[1].raw_affiliation_string | Leslie Dan Faculty of Pharmacy, University of Toronto; Li Ka Shing Knowledge Institute, Unity Health Toronto; and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. |
| authorships[4].affiliations[2].institution_ids | https://openalex.org/I126859394 |
| authorships[4].affiliations[2].raw_affiliation_string | Alberta Health Services, Edmonton, Alberta, Canada. |
| authorships[4].affiliations[3].institution_ids | https://openalex.org/I4399598460 |
| authorships[4].affiliations[3].raw_affiliation_string | Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada. |
| authorships[4].affiliations[4].institution_ids | https://openalex.org/I4399598460 |
| authorships[4].affiliations[4].raw_affiliation_string | Unity Health Toronto; and Institute of Health Policy, Management and Evaluation, |
| authorships[4].affiliations[5].institution_ids | https://openalex.org/I185261750 |
| authorships[4].affiliations[5].raw_affiliation_string | Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services, |
| authorships[4].affiliations[6].institution_ids | https://openalex.org/I185261750 |
| authorships[4].affiliations[6].raw_affiliation_string | University of Toronto, Toronto, Canada. |
| authorships[4].affiliations[7].institution_ids | https://openalex.org/I185261750, https://openalex.org/I2801816099 |
| authorships[4].affiliations[7].raw_affiliation_string | Faculty of Pharmacy, University of Toronto; ICES; and Women's College Research Institute, Toronto, Canada. |
| authorships[4].institutions[0].id | https://openalex.org/I4399598460 |
| authorships[4].institutions[0].ror | https://ror.org/012x5xb44 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4399598460 |
| authorships[4].institutions[0].country_code | |
| authorships[4].institutions[0].display_name | Unity Health Toronto |
| authorships[4].institutions[1].id | https://openalex.org/I126859394 |
| authorships[4].institutions[1].ror | https://ror.org/02nt5es71 |
| authorships[4].institutions[1].type | healthcare |
| authorships[4].institutions[1].lineage | https://openalex.org/I126859394 |
| authorships[4].institutions[1].country_code | CA |
| authorships[4].institutions[1].display_name | Alberta Health Services |
| authorships[4].institutions[2].id | https://openalex.org/I185261750 |
| authorships[4].institutions[2].ror | https://ror.org/03dbr7087 |
| authorships[4].institutions[2].type | education |
| authorships[4].institutions[2].lineage | https://openalex.org/I185261750 |
| authorships[4].institutions[2].country_code | CA |
| authorships[4].institutions[2].display_name | University of Toronto |
| authorships[4].institutions[3].id | https://openalex.org/I2801816099 |
| authorships[4].institutions[3].ror | https://ror.org/03cw63y62 |
| authorships[4].institutions[3].type | healthcare |
| authorships[4].institutions[3].lineage | https://openalex.org/I2801816099 |
| authorships[4].institutions[3].country_code | CA |
| authorships[4].institutions[3].display_name | Women's College Hospital |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Tara Gomes |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Alberta Health Services, Edmonton, Alberta, Canada., Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services,, Faculty of Pharmacy, University of Toronto; ICES; and Women's College Research Institute, Toronto, Canada., ICES, Toronto, Canada., Leslie Dan Faculty of Pharmacy, University of Toronto; Li Ka Shing Knowledge Institute, Unity Health Toronto; and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada., Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada., Unity Health Toronto; and Institute of Health Policy, Management and Evaluation,, University of Toronto, Toronto, Canada. |
| authorships[5].author.id | https://openalex.org/A5036298172 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-1911-6129 |
| authorships[5].author.display_name | Mina Tadrous |
| authorships[5].countries | CA, HK |
| authorships[5].affiliations[0].raw_affiliation_string | ICES, Toronto, Canada. |
| authorships[5].affiliations[1].institution_ids | https://openalex.org/I185261750, https://openalex.org/I2800582968 |
| authorships[5].affiliations[1].raw_affiliation_string | Faculty of Pharmacy, University of Toronto; Li Ka Shing Knowledge Institute, |
| authorships[5].affiliations[2].institution_ids | https://openalex.org/I185261750 |
| authorships[5].affiliations[2].raw_affiliation_string | Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services, |
| authorships[5].affiliations[3].institution_ids | https://openalex.org/I185261750, https://openalex.org/I2801816099 |
| authorships[5].affiliations[3].raw_affiliation_string | Leslie Dan Faculty of Pharmacy, University of Toronto; ICES; and Women’s College Research Institute, Toronto, Canada. |
| authorships[5].affiliations[4].institution_ids | https://openalex.org/I126859394 |
| authorships[5].affiliations[4].raw_affiliation_string | Alberta Health Services, Edmonton, Alberta, Canada. |
| authorships[5].affiliations[5].institution_ids | https://openalex.org/I4399598460 |
| authorships[5].affiliations[5].raw_affiliation_string | Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada. |
| authorships[5].affiliations[6].institution_ids | https://openalex.org/I4399598460 |
| authorships[5].affiliations[6].raw_affiliation_string | Unity Health Toronto; and Institute of Health Policy, Management and Evaluation, |
| authorships[5].affiliations[7].institution_ids | https://openalex.org/I185261750 |
| authorships[5].affiliations[7].raw_affiliation_string | University of Toronto, Toronto, Canada. |
| authorships[5].institutions[0].id | https://openalex.org/I4399598460 |
| authorships[5].institutions[0].ror | https://ror.org/012x5xb44 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4399598460 |
| authorships[5].institutions[0].country_code | |
| authorships[5].institutions[0].display_name | Unity Health Toronto |
| authorships[5].institutions[1].id | https://openalex.org/I126859394 |
| authorships[5].institutions[1].ror | https://ror.org/02nt5es71 |
| authorships[5].institutions[1].type | healthcare |
| authorships[5].institutions[1].lineage | https://openalex.org/I126859394 |
| authorships[5].institutions[1].country_code | CA |
| authorships[5].institutions[1].display_name | Alberta Health Services |
| authorships[5].institutions[2].id | https://openalex.org/I185261750 |
| authorships[5].institutions[2].ror | https://ror.org/03dbr7087 |
| authorships[5].institutions[2].type | education |
| authorships[5].institutions[2].lineage | https://openalex.org/I185261750 |
| authorships[5].institutions[2].country_code | CA |
| authorships[5].institutions[2].display_name | University of Toronto |
| authorships[5].institutions[3].id | https://openalex.org/I2801816099 |
| authorships[5].institutions[3].ror | https://ror.org/03cw63y62 |
| authorships[5].institutions[3].type | healthcare |
| authorships[5].institutions[3].lineage | https://openalex.org/I2801816099 |
| authorships[5].institutions[3].country_code | CA |
| authorships[5].institutions[3].display_name | Women's College Hospital |
| authorships[5].institutions[4].id | https://openalex.org/I2800582968 |
| authorships[5].institutions[4].ror | https://ror.org/01g6g9h28 |
| authorships[5].institutions[4].type | nonprofit |
| authorships[5].institutions[4].lineage | https://openalex.org/I2800582968 |
| authorships[5].institutions[4].country_code | HK |
| authorships[5].institutions[4].display_name | Li Ka Shing Foundation |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Mina Tadrous |
| authorships[5].is_corresponding | True |
| authorships[5].raw_affiliation_strings | Alberta Health Services, Edmonton, Alberta, Canada., Faculty of Pharmacy, University of Toronto, Toronto, Canada, and Pharmacy Services,, Faculty of Pharmacy, University of Toronto; Li Ka Shing Knowledge Institute,, ICES, Toronto, Canada., Leslie Dan Faculty of Pharmacy, University of Toronto; ICES; and Women’s College Research Institute, Toronto, Canada., Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada., Unity Health Toronto; and Institute of Health Policy, Management and Evaluation,, University of Toronto, Toronto, Canada. |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.jmcp.org/doi/pdf/10.18553/jmcp.2021.27.4.444 |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T12255 |
| primary_topic.field.id | https://openalex.org/fields/24 |
| primary_topic.field.display_name | Immunology and Microbiology |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2403 |
| primary_topic.subfield.display_name | Immunology |
| primary_topic.display_name | Biosimilars and Bioanalytical Methods |
| related_works | https://openalex.org/W1981336058, https://openalex.org/W2077942718, https://openalex.org/W2774189845, https://openalex.org/W2587157414, https://openalex.org/W2924476097, https://openalex.org/W3010465489, https://openalex.org/W2523259317, https://openalex.org/W2252829258, https://openalex.org/W2122265491, https://openalex.org/W2125935509 |
| cited_by_count | 3 |
| counts_by_year[0].year | 2022 |
| counts_by_year[0].cited_by_count | 2 |
| counts_by_year[1].year | 2021 |
| counts_by_year[1].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | doi:10.18553/jmcp.2021.27.4.444 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764743878 |
| best_oa_location.source.issn | 2376-0540, 2376-1032 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 2376-0540 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Journal of Managed Care & Specialty Pharmacy |
| best_oa_location.source.host_organization | https://openalex.org/P4310321168 |
| best_oa_location.source.host_organization_name | AMCP |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310321168 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://www.jmcp.org/doi/pdf/10.18553/jmcp.2021.27.4.444 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal of Managed Care & Specialty Pharmacy |
| best_oa_location.landing_page_url | https://doi.org/10.18553/jmcp.2021.27.4.444 |
| primary_location.id | doi:10.18553/jmcp.2021.27.4.444 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2764743878 |
| primary_location.source.issn | 2376-0540, 2376-1032 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 2376-0540 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Journal of Managed Care & Specialty Pharmacy |
| primary_location.source.host_organization | https://openalex.org/P4310321168 |
| primary_location.source.host_organization_name | AMCP |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310321168 |
| primary_location.license | |
| primary_location.pdf_url | https://www.jmcp.org/doi/pdf/10.18553/jmcp.2021.27.4.444 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of Managed Care & Specialty Pharmacy |
| primary_location.landing_page_url | https://doi.org/10.18553/jmcp.2021.27.4.444 |
| publication_date | 2021-04-01 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W4241819020, https://openalex.org/W100013426, https://openalex.org/W2999942204, https://openalex.org/W3022365662, https://openalex.org/W2089190513, https://openalex.org/W2991773442, https://openalex.org/W2036668944, https://openalex.org/W2020215020, https://openalex.org/W2889154468, https://openalex.org/W2907088970, https://openalex.org/W2754502404, https://openalex.org/W3002426265, https://openalex.org/W2546921546, https://openalex.org/W2885494382, https://openalex.org/W2126465300, https://openalex.org/W3047409061, https://openalex.org/W2778747082, https://openalex.org/W2600539291, https://openalex.org/W2910990828, https://openalex.org/W2545497673, https://openalex.org/W3032626619, https://openalex.org/W2066046707, https://openalex.org/W2985705185 |
| referenced_works_count | 23 |
| abstract_inverted_index.= | 131, 142, 146, 156, 177, 186, 196 |
| abstract_inverted_index.a | 56, 65, 136 |
| abstract_inverted_index.(n | 130, 141, 155, 176, 185, 195 |
| abstract_inverted_index.1, | 79 |
| abstract_inverted_index.CI | 145 |
| abstract_inverted_index.Q1 | 118 |
| abstract_inverted_index.Q2 | 121, 149, 165, 207, 221 |
| abstract_inverted_index.RC | 184, 205 |
| abstract_inverted_index.To | 34 |
| abstract_inverted_index.an | 23 |
| abstract_inverted_index.by | 128, 148, 170, 271 |
| abstract_inverted_index.in | 16, 61, 164, 206, 220, 245 |
| abstract_inverted_index.is | 55 |
| abstract_inverted_index.no | 280 |
| abstract_inverted_index.of | 2, 9, 38, 45, 59, 101, 139, 158, 160, 179, 188, 198, 200, 236, 248, 259, 275, 282 |
| abstract_inverted_index.on | 42 |
| abstract_inverted_index.or | 70 |
| abstract_inverted_index.to | 25, 96, 120, 133, 217, 255, 284 |
| abstract_inverted_index.187 | 178 |
| abstract_inverted_index.203 | 187 |
| abstract_inverted_index.30, | 83 |
| abstract_inverted_index.539 | 157 |
| abstract_inverted_index.659 | 197 |
| abstract_inverted_index.95% | 144 |
| abstract_inverted_index.IBD | 175 |
| abstract_inverted_index.RC. | 249 |
| abstract_inverted_index.The | 277 |
| abstract_inverted_index.Use | 1 |
| abstract_inverted_index.and | 47, 50, 81, 87, 111, 124, 181, 231, 241 |
| abstract_inverted_index.are | 253 |
| abstract_inverted_index.for | 6, 68, 107, 174, 183, 204, 262, 266 |
| abstract_inverted_index.has | 13 |
| abstract_inverted_index.low | 240 |
| abstract_inverted_index.not | 242 |
| abstract_inverted_index.the | 7, 36, 43, 97, 214, 234, 246, 257, 272 |
| abstract_inverted_index.use | 44 |
| abstract_inverted_index.was | 239, 269 |
| abstract_inverted_index.(Q2) | 100 |
| abstract_inverted_index.(RC) | 110 |
| abstract_inverted_index.2010 | 119 |
| abstract_inverted_index.6.9% | 173 |
| abstract_inverted_index.From | 117 |
| abstract_inverted_index.IBD. | 263 |
| abstract_inverted_index.June | 82 |
| abstract_inverted_index.This | 54 |
| abstract_inverted_index.drug | 75 |
| abstract_inverted_index.have | 279 |
| abstract_inverted_index.this | 168, 267 |
| abstract_inverted_index.were | 89 |
| abstract_inverted_index.with | 30, 135, 172 |
| abstract_inverted_index.$49.9 | 218 |
| abstract_inverted_index.13.7% | 140 |
| abstract_inverted_index.13.8% | 154 |
| abstract_inverted_index.20.2% | 194 |
| abstract_inverted_index.2010, | 80 |
| abstract_inverted_index.2019, | 122, 166 |
| abstract_inverted_index.2019. | 84, 208, 222 |
| abstract_inverted_index.2022. | 102, 150 |
| abstract_inverted_index.26.6% | 182 |
| abstract_inverted_index.4,073 | 132 |
| abstract_inverted_index.75.7% | 129 |
| abstract_inverted_index.764). | 189 |
| abstract_inverted_index.bowel | 113 |
| abstract_inverted_index.costs | 88 |
| abstract_inverted_index.drugs | 5, 21 |
| abstract_inverted_index.offer | 22 |
| abstract_inverted_index.study | 35, 58, 268 |
| abstract_inverted_index.their | 237 |
| abstract_inverted_index.total | 161, 201 |
| abstract_inverted_index.users | 126, 152, 163, 192, 203 |
| abstract_inverted_index.using | 91 |
| abstract_inverted_index.(IBD). | 115 |
| abstract_inverted_index.109.7% | 212 |
| abstract_inverted_index.2,712) | 180 |
| abstract_inverted_index.3,256) | 199 |
| abstract_inverted_index.3,905) | 159 |
| abstract_inverted_index.8,142; | 143 |
| abstract_inverted_index.costly | 3 |
| abstract_inverted_index.during | 213 |
| abstract_inverted_index.effect | 37 |
| abstract_inverted_index.ensure | 26 |
| abstract_inverted_index.health | 27 |
| abstract_inverted_index.models | 95 |
| abstract_inverted_index.needed | 254 |
| abstract_inverted_index.policy | 251 |
| abstract_inverted_index.public | 74 |
| abstract_inverted_index.recent | 17 |
| abstract_inverted_index.robust | 31 |
| abstract_inverted_index.second | 98 |
| abstract_inverted_index.study, | 215 |
| abstract_inverted_index.system | 28 |
| abstract_inverted_index.uptake | 235, 258 |
| abstract_inverted_index.years. | 18 |
| abstract_inverted_index.7,158), | 134 |
| abstract_inverted_index.Canada, | 63 |
| abstract_inverted_index.Despite | 224 |
| abstract_inverted_index.Dynamic | 250 |
| abstract_inverted_index.Funding | 265 |
| abstract_inverted_index.Health. | 276 |
| abstract_inverted_index.January | 78 |
| abstract_inverted_index.Ontario | 273 |
| abstract_inverted_index.authors | 278 |
| abstract_inverted_index.between | 77, 228 |
| abstract_inverted_index.chronic | 10 |
| abstract_inverted_index.disease | 114 |
| abstract_inverted_index.improve | 256 |
| abstract_inverted_index.listing | 40 |
| abstract_inverted_index.million | 219 |
| abstract_inverted_index.program | 76 |
| abstract_inverted_index.quarter | 99 |
| abstract_inverted_index.through | 72 |
| abstract_inverted_index.uptake. | 32 |
| abstract_inverted_index.However, | 19 |
| abstract_inverted_index.Ministry | 274 |
| abstract_inverted_index.Ontario, | 62 |
| abstract_inverted_index.although | 167 |
| abstract_inverted_index.analyses | 104 |
| abstract_inverted_index.biologic | 4, 66 |
| abstract_inverted_index.differed | 169 |
| abstract_inverted_index.diseases | 12 |
| abstract_inverted_index.explored | 105 |
| abstract_inverted_index.increase | 138 |
| abstract_inverted_index.interest | 283 |
| abstract_inverted_index.Biologics | 209 |
| abstract_inverted_index.Ontario's | 73 |
| abstract_inverted_index.Quarterly | 85 |
| abstract_inverted_index.Secondary | 103 |
| abstract_inverted_index.amounting | 216 |
| abstract_inverted_index.conflicts | 281 |
| abstract_inverted_index.different | 244 |
| abstract_inverted_index.differing | 225 |
| abstract_inverted_index.disclose. | 285 |
| abstract_inverted_index.dispensed | 64 |
| abstract_inverted_index.formulary | 39 |
| abstract_inverted_index.increased | 14, 127, 211 |
| abstract_inverted_index.innovator | 49, 229 |
| abstract_inverted_index.rheumatic | 108 |
| abstract_inverted_index.smoothing | 94 |
| abstract_inverted_index.treatment | 8, 247 |
| abstract_inverted_index.Biosimilar | 151 |
| abstract_inverted_index.Etanercept | 190 |
| abstract_inverted_index.biologics, | 233 |
| abstract_inverted_index.biologics. | 52 |
| abstract_inverted_index.biosimilar | 20, 51, 191 |
| abstract_inverted_index.conditions | 109 |
| abstract_inverted_index.etanercept | 48, 71, 125, 202, 232 |
| abstract_inverted_index.forecasted | 90, 137 |
| abstract_inverted_index.indication | 171 |
| abstract_inverted_index.infliximab | 46, 69, 123, 162, 230 |
| abstract_inverted_index.noticeably | 243 |
| abstract_inverted_index.strategies | 41, 252 |
| abstract_inverted_index.biosimilars | 238 |
| abstract_inverted_index.contributed | 270 |
| abstract_inverted_index.exponential | 93 |
| abstract_inverted_index.individuals | 60 |
| abstract_inverted_index.opportunity | 24 |
| abstract_inverted_index.represented | 153, 193 |
| abstract_inverted_index.utilization | 86, 106 |
| abstract_inverted_index.7,438-8,847) | 147 |
| abstract_inverted_index.biosimilars, | 260 |
| abstract_inverted_index.expenditures | 210 |
| abstract_inverted_index.inflammatory | 11, 112 |
| abstract_inverted_index.particularly | 261 |
| abstract_inverted_index.prescription | 67 |
| abstract_inverted_index.restrictions | 227 |
| abstract_inverted_index.Holt-Winters' | 92 |
| abstract_inverted_index.reimbursement | 226 |
| abstract_inverted_index.significantly | 15 |
| abstract_inverted_index.sustainability | 29 |
| abstract_inverted_index.<b>METHODS:</b> | 53 |
| abstract_inverted_index.<b>RESULTS:</b> | 116 |
| abstract_inverted_index.cross-sectional | 57 |
| abstract_inverted_index.<b>OBJECTIVE:</b> | 33 |
| abstract_inverted_index.<b>BACKGROUND:</b> | 0 |
| abstract_inverted_index.<b>CONCLUSIONS:</b> | 223 |
| abstract_inverted_index.<b>DISCLOSURES:</b> | 264 |
| cited_by_percentile_year.max | 96 |
| cited_by_percentile_year.min | 89 |
| corresponding_author_ids | https://openalex.org/A5036298172 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 6 |
| corresponding_institution_ids | https://openalex.org/I126859394, https://openalex.org/I185261750, https://openalex.org/I2800582968, https://openalex.org/I2801816099, https://openalex.org/I4399598460 |
| citation_normalized_percentile.value | 0.50167355 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |